Filing Details

Accession Number:
0001437749-23-026160
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-18 11:48:02
Reporting Period:
2023-09-15
Accepted Time:
2023-09-18 11:48:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
768408 Cyanotech Corp CYAN Medicinal Chemicals & Botanical Products (2833) 911206026
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1201156 / A Michael Davis Cyanotech Corporation
73-4460 Queen Kaahumanu Hwy #102
Kailua-Kona HI 96740
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Cyanotech Corporation Common Stock Acquisiton 2023-09-15 3,245 $0.85 594,460 No 4 P Indirect By self as trustee of the Michael Arlen Davis Revocable Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By self as trustee of the Michael Arlen Davis Revocable Trust
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Cyanotech Corporation Common Stock 12,119 Direct
Cyanotech Corporation Common Stock 31,250 Indirect By Spouse
Cyanotech Corporation Common Stock 150,000 Indirect By self as co-trustee for the Nyracai Davis Irr. Trust and the Nettizanne J. Davis Irr. Trust
Cyanotech Corporation Common Stock 58,000 Indirect By self as trustee for Nettizanne Johnstone Davis GST Exempt Trust
Cyanotech Corporation Common Stock 58,789 Indirect By self as trustee for Nyracai Johnstone Davis GST Exempt Trust
Footnotes
  1. The price reported is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.83 to $0.835, inclusive. The reporting person undertakes to provide to Cyanotech Corporation, any security holder of Cyanotech Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.